Trial reportJBRA assisted reproduction2025
Evaluation of the effects of the Stop GnRH agonist with the letrozole protocol in poor ovarian responders: ABOTH randomized controlled trial.
Trial report in JBRA assisted reproduction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stop gonadotropin-releasing hormone-agonist protocol not superior to antagonist protocol on the outcomes of assisted reproductive techniques in poor responders: A randomized clinical trial.International journal of reproductive biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to evaluate the effect of a stop gonadotropin-releasing hormone (GnRH) agonist with letrozole protocol in improving in vitro fertilization (IVF) cycles in poor ovarian responders (PORs) and to suggest a suitable new ovulation stimulation protocol for this group of infertile women.
methodsThis randomized controlled trial was conducted at the Infertility Center of Taleghani Hospital, Tehran, Iran, from August 2024 to December 2024. The participants were 60 women who fulfilled the POSEIDON Group 4 criteria and had poor ovarian response in their previous IVF cycles. Participants were randomly assigned to the study and control groups and underwent a new IVF cycle. The study group underwent a new cycle with a stop agonist using the letrozole protocol, and the control group underwent the conventional stimulation protocol, which was the same as the previous cycle.
resultsCompared with the conventional protocol, the stop-GnRH agonist and letrozole protocols resulted in a significantly greater number of follicles >13 mm on the day of human chorionic gonadotropin (hCG) administration and a greater number of mature oocytes retrieved, with a significantly greater number of total embryos obtained at days 3 and 5 and a greater number of top-quality embryos. The mean biochemical and clinical pregnancy rates were similar between groups.
conclusionsThe stop-GnRH agonist and letrozole protocol is a short and original protocol that seems to yield better outcomes for patients and may offer promising results for treating POSEIDON Group 4 patients with previous failed IVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.